ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will participate in the SVB Leerink Global Healthcare conference (Virtual).
Conference Presentation Details:
SVB Leerink Global Healthcare Conference Wednesday, February 15, 2023, at 12:00 pm ET (6:00 pm CET)
A webcast and replay of the presentation will be made available on the Molecular Partners website.
About Molecular Partners AG:
Molecular Partners AG is a clinical-stage biotech company developing DARPin therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics in the areas of oncology and infectious disease and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas. www.molecularpartners.com; Find us on Twitter - @MolecularPrtnrs
For further details, please contact:
Seth Lewis, Head of Investor Relations & Strategy
Concord, Massachusetts, U.S.
seth.lewis@molecularpartners.com
Tel: +1 781 420 2361
Antonio Ligi, Head of Communications
Zürich-Schlieren, Switzerland
antonio.ligi@molecularpartners.com
Tel: +41 79 723 36 81
![[Chia sẻ] Để có ảnh đẹp trong những ngày Tết](http://cdn.trangcongnghe.vn/thumb/160x240/2017-01/thumbs/chia-se-de-co-anh-dep-trong-nhung-ngay-tet_1.jpeg)
